From Seekingalpha · Gary Aquilina · · 40s
COMPASS Pathways FDA Valuation
COMPASS Pathways valued at 0.57x Spravato sales with FDA fast-track approval expected.
In brief
COMPASS Pathways valued at 0.57x Spravato sales with FDA fast-track approval expected. COMPASS Pathways' stock is valued at 0.57x Spravato's annual sales after Phase 3 trials matched FDA guidance for treatment-resistant depression. Originally reported by Seekingalpha.
FDA Fast-Track Approval
COMPASS Pathways' COMP360 trial design matched FDA guidance and achieved statistically significant efficacy similar to Spravato.
Valuation at 0.57x Sales
COMPASS Pathways holds $433.3 million cash, valued at 0.57x Spravato's annual sales for treatment-resistant depression.
FDA Review Timeline
COMP360's NDA is expected for a fast-track FDA decision this quarter with potential delays if the NDA slips past Q4.
The headline
COMPASS Pathways' stock is valued at 0.57x Spravato's annual sales after Phase 3 trials matched FDA guidance for treatment-resistant depression.
